ORA

Company

ORA develops one asset, in phase 2 (cis-UCA in dry eye syndrome). Mostly small molecule acting on inflammation.

1
Asset
Furthest stage
Phase 2
1
Trial
0
Signals

Pipeline

1
  • cis-UCA

    Cis-urocanic acid anti-inflammatory modulator for ocular surface indications.

    Phase 2, Small molecule, Inflammation, dry eye syndrome, Partner

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials6
  • Similar companies6

Intelligence